

Literatur Suchtforschung (Auswahl, alphabetisch):

Abdeta T, Tolessa D, Adorjan K, Abera M. Prevalence, withdrawal symptoms and associated factors of khat chewing among students at Jimma University in Ethiopia. *BMC Psychiatry*. 2017 Apr 17;17(1):142. doi: 10.1186/s12888-017-1284-4. PubMed PMID: 28412950; PubMed Central PMCID: PMC5392995.

Adorjan K, Odenwald M, Widmann M, Tesfaye M, Tessema F, Toennes S, Suleman S, Papiol S, Soboka M, Mekonnen Z, Rockstroh B, Rietschel M, Pogarell O, Susser E, Schulze TG. Khat use and occurrence of psychotic symptoms in the general male population in Southwestern Ethiopia: evidence for sensitization by traumatic experiences. *World Psychiatry*. 2017 Oct;16(3):323. doi: 10.1002/wps.20470. PubMed PMID: 28941092; PubMed Central PMCID: PMC5608818.

Adorjan K, Koller G, Pogarell O. [Multimodal treatment of patients with addictions after detoxification]. *MMW Fortschr Med*. 2015 Aug 20;157(14):53-5. doi: 10.1007/s15006-015-3421-7. German. PubMed PMID: 26289888.

Adorjan K, Thoma C, Tchipeva E, Janjic K, Leidger A, Hoch E, Koller G, Falkai P, Pogarell O, Karch S Ein wirksames Behandlungskonzept für Patienten mit Suchterkrankungen. *MMW Fortschr Med* 2017; 159 Suppl 6: 1-5.

Engelbregt HJ, Keeser D, van Eijk L, Suiker EM, Eichhorn D, Karch S, Deijen JB, Pogarell O. Short and long-term effects of sham-controlled prefrontal EEG-neurofeedback training in healthy subjects. *Clin Neurophysiol*. 2016 Apr;127(4):1931-7. doi: 10.1016/j.clinph.2016.01.004. Epub 2016 Jan 22. PubMed PMID: 26971473.

Campanella S, Pogarell O, Boutros N. Event-related potentials in substance use disorders: a narrative review based on articles from 1984 to 2012. *Clin EEG Neurosci*. 2014 Apr;45(2):67-76. doi: 10.1177/1550059413495533. Epub 2013 Oct 8. Review. PubMed PMID: 24104954.

Costa A, Riedel M, Pogarell O, Menzel-Zelnitschek F, Schwarz M, Reiser M, Möller HJ, Rubia K, Meindl T, Ettinger U. Methylphenidate effects on neural activity during response inhibition in healthy humans. *Cereb Cortex*. 2013 May;23(5):1179-89. doi: 10.1093/cercor/bhs107. Epub 2012 May 10. PubMed PMID: 22581848.

Grüne B, Piontek D, Slecicka P, Kraus L, Pogarell O. Drinking Location and Drinking Culture and Their Association With Alcohol Use Among Girls and Boys in Europe. *J Stud Alcohol Drugs*. 2017 Jul;78(4):549-557. PubMed PMID: 28728637.

Grüne B, Piontek D, Pogarell O, Grübl A, Groß C, Reis O, Zimmermann US, Kraus L. Acute alcohol intoxication among adolescents-the role of the context of drinking. *Eur J Pediatr*. 2017 Jan;176(1):31-39. doi: 10.1007/s00431-016-2797-4. Epub 2016 Nov 12. PubMed PMID: 27838776.

Günthner A, Weissinger V, Fleischmann H, Veltrup C, Jäpel B, Längle G, Amann K, Hoch E, Mann K. [Health Care Organization - The New German S3-Guideline on Alcohol-Related Disorders and its Relevance for Health Care]. *Rehabilitation (Stuttg)*. 2018 Jan 22. doi: 10.1055/s-0043-118955. [Epub ahead of print] German. PubMed PMID: 29359282.

Havemann-Reinecke U, Hoch E, Preuss UW, Kiefer F, Batra A, Gerlinger G, Hauth I. [On the legalization debate of non-medical cannabis consumption : Position paper of the German Association for Psychiatry, Psychotherapy and Psychosomatics]. *Nervenarzt*. 2017 Mar;88(3):291-298. doi: 10.1007/s00115-016-0248-0. German. PubMed PMID: 27981374.

Hoch E, Preuss UW, Ferri M, Simon R. Digital Interventions for Problematic Cannabis Users in Non-Clinical Settings: Findings from a Systematic Review and Meta-Analysis. *Eur Addict Res*. 2016;22(5):233-42. doi: 10.1159/000445716. Epub 2016 May 4. Review. PubMed PMID: 27160333.

Hoch E, Bonnetn U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW. Risks associated with the non-medicinal use of cannabis. *Dtsch Arztebl Int*. 2015 Apr 17;112(16):271-8. doi: 10.3238/arztebl.2015.0271. Review. PubMed PMID: 25939318; PubMed Central PMCID: PMC4442549.

Hoch E, Bühringer G, Pixa A, Dittmer K, Henker J, Seifert A, Wittchen HU. CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. *Drug Alcohol Depend.* 2014 Jan 1;134:185-193. doi: 10.1016/j.drugalcdep.2013.09.028. Epub 2013 Oct 8. PubMed PMID: 24176199.

Hoch E, Noack R, Henker J, Pixa A, Höfler M, Behrendt S, Bühringer G, Wittchen HU. Efficacy of a targeted cognitive-behavioral treatment program for cannabis use disorders (CANDIS). *Eur Neuropsychopharmacol.* 2012 Apr;22(4):267-80. doi: 10.1016/j.euroneuro.2011.07.014. Epub 2011 Aug 24. PubMed PMID: 21865014.

Hoch, E., Friemel, C. & Schneider, M. (2018). *Cannabis: Potential und Risiko. Eine wissenschaftliche Analyse.* Heidelberg: Springer.

Hoch, E. & Rohrbacher, H. (2017). *CANDIS: Modular Treatment for Cannabis Use Disorders.* Handbook of Cannabis and Related Pathologies. Elsevier. <http://dx.doi.org/10.1016/B978-0-12-800756-3.00130-7>.

Hoch, E., Zimmermann, P., Henker, J., Rohrbacher, H., Noack, R., Bühringer, G., Wittchen, H.-U. (2017). *CANDIS Curriculum. A Marijuana Treatment Program for Youth and Adults.* Hazelden: Betty Ford Foundation.

Kambeitz J, la Fougère C, Werner N, Pogarell O, Riedel M, Falkai P, Ettinger U. Nicotine-dopamine-transporter interactions during reward-based decision making. *Eur Neuropsychopharmacol.* 2016 Jun;26(6):938-47. doi: 10.1016/j.euroneuro.2016.03.011. Epub 2016 Apr 22. PubMed PMID: 27112968.

Karch S, Loy F, Krause D, Schwarz S, Kiesewetter J, Segmiller F, Chrobok AI, Keeser D, Pogarell O. Increased Event-Related Potentials and Alpha-, Beta-, and Gamma-Activity Associated with Intentional Actions. *Front Psychol.* 2016 Jan 22;7:7. doi: 10.3389/fpsyg.2016.00007. eCollection 2016. PubMed PMID: 26834680; PubMed Central PMCID: PMC4722116.

Karch S, Keeser D, Hümmer S, Paolini M, Kirsch V, Karali T, Kupka M, Rauchmann BS, Chrobok A, Blautzik J, Koller G, Ertl-Wagner B, Pogarell O. Modulation of Craving Related Brain Responses Using Real-Time fMRI in Patients with Alcohol Use Disorder. *PLoS One.* 2015 Jul 23;10(7):e0133034. doi: 10.1371/journal.pone.0133034. eCollection 2015. PubMed PMID: 26204262; PubMed Central PMCID: PMC4512680.

Kasparbauer AM, Rujescu D, Riedel M, Pogarell O, Costa A, Meindl T, la Fougère C, Ettinger U. Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability. *Neuropsychopharmacology.* 2015 Feb;40(3):736-45. doi: 10.1038/npp.2014.240. Epub 2014 Sep 15. PubMed PMID: 25220215; PubMed Central PMCID: PMC4289963.

Kreuter M, Nowak D, Rütger T, Hoch E, Thomasius R, Vogelberg C, Brockstedt M, Hellmann A, Gohlke H, Jany B, Loddenkemper R. [Cannabis--Position Paper of the German Respiratory Society (DGP)]. *Pneumologie.* 2016 Feb;70(2):87-97. doi: 10.1055/s-0042-100040. Epub 2016 Mar 2. German. PubMed PMID: 26935046.

Koller G, Preuss U, Lü O, Soyka M, Pogarell O. Alcohol-Dependent Subjects Show Different Personality Traits Compared With Subjects With Multiple Substance Dependence: Preliminary Data. *J Addict Med.* 2015 Jul-Aug;9(4):257-60. doi: 10.1097/ADM.000000000000126. PubMed PMID: 26079976.

Koller G. [Long-term treatment of alcoholism]. *Fortschr Neurol Psychiatr.* 2013 Nov;81(11):655-65; quiz 666. doi: 10.1055/s-0033-1355556. Epub 2013 Nov 5. Review. German. PubMed PMID: 24194059.

Krause D, Plörer D, Koller G, Martin G, Winter C, Adam R, Canolli M, Al-Iassin J, Musselmann R, Walcher S, Schäfer F, Pogarell O. High Concomitant Misuse of Fentanyl in Subjects on Opioid Maintenance Treatment. *Subst Use Misuse.* 2017 Apr 16;52(5):639-645. doi: 10.1080/10826084.2016.1246571. Epub 2017 Feb 3. PubMed PMID: 28157415.

Mann K, Batra A, Fauth-Bühler M, Hoch E; and the Guideline Group. German Guidelines on Screening, Diagnosis and Treatment of Alcohol Use Disorders. *Eur Addict Res.* 2017;23(1):45-60. doi: 10.1159/000455841. Epub 2017 Feb 9. PubMed PMID: 28178695.

Mueller S, Costa A, Keeser D, Pogarell O, Berman A, Coates U, Reiser MF, Riedel M, Möller HJ, Ettinger U, Meindl T. The effects of methylphenidate on whole brain intrinsic functional connectivity. *Hum Brain Mapp.* 2014 Nov;35(11):5379-88. doi: 10.1002/hbm.22557. Epub 2014 May 23. PubMed PMID: 24862742.

Mühlig S, Andreas S, Batra A, Petersen KU, Hoch E, Rütther T. [Psychiatric comorbidities with tobacco-related disorders]. *Nervenarzt.* 2016 Jan;87(1):46-52. doi: 10.1007/s00115-015-0020-x. German. PubMed PMID: 26597273.

Oppek K, Koller G, Zwergal A, Pogarell O. Intravenous administration and abuse of bupropion: a case report and a review of the literature. *J Addict Med.* 2014 Jul-Aug;8(4):290-3. doi: 10.1097/ADM.0000000000000044. PubMed PMID: 24950138.

Preuss UW, Wurst FM, Ridinger M, Rujescu D, Fehr C, Koller G, Bondy B, Wodarz N, Soyka M, Zill P. Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: results from a large multicenter association study. *Drug Alcohol Depend.* 2013 Dec 1;133(2):459-67. doi: 10.1016/j.drugalcdep.2013.07.002. Epub 2013 Jul 30. PubMed PMID: 23906995.

Preuss UW, Gouzoulis-Mayfrank E, Havemann-Reinecke U, Schäfer I, Beutel M, Hoch E, Mann KF. Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines. *Eur Arch Psychiatry Clin Neurosci.* 2017 Apr 24. doi: 10.1007/s00406-017-0801-2. [Epub ahead of print] Review. PubMed PMID: 28439723.

Preuss UW, Koller G, Samochowiec A, Zill P, Samochowiec J, Kucharska-Mazur J, Wong J, Soyka M. Serotonin and Dopamine Candidate Gene Variants and Alcohol- and Non-Alcohol-Related Aggression. *Alcohol Alcohol.* 2015 Nov;50(6):690-9. doi: 10.1093/alcalc/agg057. Epub 2015 Jun 3. PubMed PMID: 26041607.

Proebstl L, Kamp F, Koller G, Soyka M. Cognitive Deficits in Methamphetamine Users: How Strong is The Evidence? *Pharmacopsychiatry.* 2018 Jan 15. doi: 10.1055/s-0043-123471. [Epub ahead of print] PubMed PMID: 29334687.

Quaglio G, Schellekens A, Blankers M, Hoch E, Karapiperis T, Esposito G, Brand H, Nutt D, Kiefer F. A Brief Outline of the Use of New Technologies for Treating Substance Use Disorders in the European Union. *Eur Addict Res.* 2017;23(4):177-181. doi: 10.1159/000478904. Epub 2017 Aug 12. PubMed PMID: 28803249.

Rominger A, Cumming P, Xiong G, Koller G, Förster S, Zwergal A, Karamatskos E, Bartenstein P, La Fougère C, Pogarell O. Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: a [18F]fallypride PET study. *Eur Neuropsychopharmacol.* 2013 Nov;23(11):1606-10. doi: 10.1016/j.euroneuro.2013.01.009. Epub 2013 Feb 27. PubMed PMID: 23452563.

Rominger A, Cumming P, Xiong G, Koller G, Böning G, Wulff M, Zwergal A, Förster S, Reilhac A, Munk O, Soyka M, Wängler B, Bartenstein P, la Fougère C, Pogarell O. [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics. *Addict Biol.* 2012 Mar;17(2):490-503. doi: 10.1111/j.1369-1600.2011.00355.x. Epub 2011 Oct 3. PubMed PMID: 22023291.

Rütther T, Kiss A, Eberhardt K, Linhardt A, Kröger C, Pogarell O. Evaluation of the cognitive behavioral smoking reduction program "Smoke_less": a randomized controlled trial. *Eur Arch Psychiatry Clin Neurosci.* 2017 Jun 14. doi: 10.1007/s00406-017-0818-6. [Epub ahead of print] PubMed PMID: 28616772.

Rütther T, Ruderer A, Wirth C, Schuler V, Lang V, Linhardt A, Kröger CB, Pogarell O. Smoking Cessation Program for Inpatients with Substance Use Disorder: A Quasi-Randomized Controlled Trial of Feasibility and Efficacy. *Eur Addict Res.* 2016;22(5):268-76. doi: 10.1159/000446430. Epub 2016 Jun 9. PubMed PMID: 27287751.

Rütther T, Wissen F, Linhardt A, Aichert DS, Pogarell O, de Vries H. Electronic Cigarettes-Attitudes and Use in Germany. *Nicotine Tob Res.* 2016 May;18(5):660-9. doi: 10.1093/ntr/ntv188. Epub 2015 Sep 18. PubMed PMID: 26385930.

Rütther T, Hagedorn D, Schiela K, Schettgen T, Osiander-Fuchs H, Schober W. Nicotine delivery efficiency of first- and second-generation e-cigarettes and its impact on relief of craving during the acute phase of use. *Int J Hyg*

Environ Health. 2017 Oct 28. pii: S1438-4639(17)30511-4. doi: 10.1016/j.ijheh.2017.10.012. [Epub ahead of print] PubMed PMID: 29129555.

Rüther T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, Gorwood P, Möller HJ; European Psychiatric Association. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. *Eur Psychiatry*. 2014 Feb;29(2):65-82. doi: 10.1016/j.eurpsy.2013.11.002. Epub 2014 Jan 30. PubMed PMID: 24485753.

Soyka M, Koller G, Proebstl L, Kamp F, Franke A, Schmidt P, Baumgärtner G, Schacht-Jablonowsky M, Sievert A, Straif M, Hamdorf W. [Prevalence and Therapy of Crystal Methamphetamine Dependence]. *Fortschr Neurol Psychiatr*. 2017 Feb;85(2):92-99. doi: 10.1055/s-0042-119862. Epub 2017 Feb 24. Review. German. PubMed PMID: 28235211.

Soyka M, Zill P, Koller G, Samochowiec A, Grzywacz A, Preuss UW. Val158Met COMT polymorphism and risk of aggression in alcohol dependence. *Addict Biol*. 2015 Jan;20(1):197-204. doi: 10.1111/adb.12098. Epub 2013 Oct 3. PubMed PMID: 24118473.

Soyka M, Preuss U, Hoch E. [Cannabis-induced disorders]. *Nervenarzt*. 2017 Mar;88(3):311-325. doi: 10.1007/s00115-017-0281-7. Review. German. PubMed PMID: 28236096.

Soyka, M., Preuss, U. & Hoch, E. (2017). Cannabisinduzierte Störungen. *Der Nervenarzt*. <http://dx.doi.org/DOI:10.1007/s00115-017-0281-7>.

Thomasius R, Sack PM, Arnaud N, Hoch E. [Treatment of alcohol-related disorders in children and adolescents: Age-specific treatment recommendations from the new interdisciplinary S3-guideline]. *Z Kinder Jugendpsychiatr Psychother*. 2016;44(4):295-303; quiz 304-5. doi: 10.1024/1422-4917/a000435. German. PubMed PMID: 27434689.